Literature DB >> 27916996

A New Agent in the Strategy to Cure AIDS.

John A Zaia1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27916996      PMCID： PMC5154490          DOI： 10.1038/mt.2016.194

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  18 in total

1.  A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.

Authors:  A Löffler; P Kufer; R Lutterbüse; F Zettl; P T Daniel; J M Schwenkenbecher; G Riethmüller; B Dörken; R C Bargou
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

Review 2.  Targeting T cells with bispecific antibodies for cancer therapy.

Authors:  Lawrence G Lum; Archana Thakur
Journal:  BioDrugs       Date:  2011-12-01       Impact factor: 5.807

3.  Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells.

Authors:  Michael M Lederman; Leonard Calabrese; Nicholas T Funderburg; Brian Clagett; Kathy Medvik; Hector Bonilla; Barbara Gripshover; Robert A Salata; Alan Taege; Michelle Lisgaris; Grace A McComsey; Elizabeth Kirchner; Jane Baum; Carey Shive; Robert Asaad; Robert C Kalayjian; Scott F Sieg; Benigno Rodriguez
Journal:  J Infect Dis       Date:  2011-10-15       Impact factor: 5.226

Review 4.  Functions of the HIV-1 matrix protein p17.

Authors:  Simona Fiorentini; Elena Marini; Sonia Caracciolo; Arnaldo Caruso
Journal:  New Microbiol       Date:  2006-01       Impact factor: 2.479

5.  Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity.

Authors:  U D Staerz; M J Bevan
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

6.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors:  Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2013-03-25       Impact factor: 91.245

Review 7.  Latency reversal and viral clearance to cure HIV-1.

Authors:  David M Margolis; J Victor Garcia; Daria J Hazuda; Barton F Haynes
Journal:  Science       Date:  2016-07-22       Impact factor: 47.728

8.  Monoclonal TCR-redirected tumor cell killing.

Authors:  Nathaniel Liddy; Giovanna Bossi; Katherine J Adams; Anna Lissina; Tara M Mahon; Namir J Hassan; Jessie Gavarret; Frayne C Bianchi; Nicholas J Pumphrey; Kristin Ladell; Emma Gostick; Andrew K Sewell; Nikolai M Lissin; Naomi E Harwood; Peter E Molloy; Yi Li; Brian J Cameron; Malkit Sami; Emma E Baston; Penio T Todorov; Samantha J Paston; Rebecca E Dennis; Jane V Harper; Steve M Dunn; Rebecca Ashfield; Andy Johnson; Yvonne McGrath; Gabriela Plesa; Carl H June; Michael Kalos; David A Price; Annelise Vuidepot; Daniel D Williams; Deborah H Sutton; Bent K Jakobsen
Journal:  Nat Med       Date:  2012-06       Impact factor: 53.440

9.  Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors.

Authors:  Hongbing Yang; Sandrine Buisson; Giovanna Bossi; Zoë Wallace; Gemma Hancock; Chun So; Rebecca Ashfield; Annelise Vuidepot; Tara Mahon; Peter Molloy; Joanne Oates; Samantha J Paston; Milos Aleksic; Namir J Hassan; Bent K Jakobsen; Lucy Dorrell
Journal:  Mol Ther       Date:  2016-06-06       Impact factor: 11.454

10.  A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"?

Authors:  Michael M Lederman; Paula M Cannon; Judith S Currier; Carl H June; Hans Peter Kiem; Daniel R Kuritzkes; Sharon R Lewin; David M Margolis; Joseph M McCune; John W Mellors; Timothy W Schacker; Rafick P Sekaly; Pablo Tebas; Bruce D Walker; Daniel C Douek
Journal:  Pathog Immun       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.